Sage Journals: Discover world-class research

Abstract

Background

Intravenous unfractionated heparin infusion is often used to minimize the duration of time without anticoagulation around delivery in pregnant patients with high thrombotic risk. Activated partial thromboplastin time is commonly used to monitor and adjust heparin dose. However, using activated partial thromboplastin time is problematic in pregnancy because activated partial thromboplastin time response to unfractionated heparin is attenuated due to elevated Factor VIII levels and may lead to incorrect dosing.

Case

We report a case of deep venous thrombosis occurring in a term pregnancy managed by intravenous unfractionated heparin adjusted using anti-Xa level around the time of delivery. We modified the intravenous unfractionated heparin nomogram by using anti-Xa levels instead of activated partial thromboplastin time and observed lower dosing of unfractionated heparin than otherwise required to achieve and maintain target levels.

Conclusion

This report demonstrates the feasibility and effectiveness of using anti-Xa level to monitor and adjust intravenous unfractionated heparin infusion in pregnancy.

Keywords

Peripartum heparin monitoring anti-Xa level venous thromboembolism

Get full access to this article

View all access options for this article.

References

Chan

Rey

Kent

, et al. Venous thromboembolism and antithrombotic therapy in pregnancy. SOGC CPG No. 308. J Obstet Gynaecol Can 2014; 36: 527–553.

McLintock

Anticoagulation therapy in pregnant women with mechanical prosthetic heart valves: no easy option. Thromb Res 2011; 127(Suppl 3): S56–S60.

Garcia

Baglin

Weitz

, et al. Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis, 9th edn: ACCP Guidelines. Chest 2012; 141: e24S–e43S.

Whitfield

Lele

Levy

Effect of pregnancy on the relationship between concentration and the anticoagulant action of heparin. Clin Pharmacol Ther 1983; 34: 23–28.

Chunilal

Young

Johnston

, et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002; 87: 92–97.

Raschke

Guidry

Foley

MR.

Apparent heparin resistance from elevated factor VIII during pregnancy. Obstet Gynecol 2000; 96: 804–806.

Guervil

Rosenberg

Winterstein

, et al. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 2011; 45: 861

Rosborough

TK.

Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time. Pharmacotherapy 1999; 19: 760–766.

Smith

Wheeler

KE.

Weight-based heparin protocol using antifactor Xa monitoring. Am J Health Syst Pharm 2010; 67: 371–374.

10.

Hirsh

Drug therapy. N Engl J Med 1991; 324: 1565–1574.

11.

Levine

Hirsh

Gent

, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49–56.

12.

Brill Edwards

Ginsberg

Johnston

, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104–109.

13.

Van den Besselaar

AHMP

Meeuwise-Braun

Bertina

RM.

Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990; 63: 16–23.

14.

Casele

Laifer

SA.

Hemorrhagic complication of anticoagulation during pregnancy in a woman with lupus anticoagulant. Obstet Gynecol 1997; 90: 646–647.

15.

Garcia

Baglin

Weitz

, et al. Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 9th edn. Chest 2012; 141: 24S–43S.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB